Navigation Links
Fleming Pharmaceuticals Now Ready to Step Up Production of Nuclear Radiation Safeguard, ThyroShield®
Date:4/21/2011

ST. LOUIS, April 21, 2011 /PRNewswire/ -- Fleming Pharmaceuticals, maker of ThyroShield®– the only FDA approved liquid potassium iodide product indicated for thyroid protection in radiation emergencies – announced today that it has implemented the changes necessary to ramp up production to meet increased domestic and international demand.  

ThyroShield is an over-the-counter iodide solution which, when taken orally, saturates the thyroid gland so radioactive iodine cannot be absorbed. ThyroShield is especially effective for babies and children, who are most at risk during radiation exposure.

"The March 11 incident at Japan's Fukushima Daiichi power plant has increased awareness of the need for preparedness in the event of a major nuclear emergency," stated Phill Dritsas, president of Fleming Pharmaceuticals. "Based on the number of inquiries we have received in the past month from governments, hospitals and others around the world, it is clear to us that we need to do everything within our power here at Fleming to help meet the need for global and domestic relief. We've responded by taking steps to ensure that we can significantly increase production of ThyroShield."  

Working closely with the FDA, Fleming Pharmaceuticals has qualified a new potassium iodide (KI) supplier to ensure a steady supply of quality raw materials to manufacture ThyroShield. The company has also established new agreements with vendors to shorten lead times needed to complete orders for ThyroShield package components such as bottles, caps and droppers. Finally, Fleming Pharmaceuticals has completed a thorough audit to identify production line logistics that can be immediately implemented to fulfill any significant new orders for ThyroShield.

"ThyroShield was developed under the Orphan Drug Act – a federal law designed to encourage the development of pharmaceuticals that have limited commercial potential," Dritsas said. "It has always been made-to-order, rather than produced in mass quantities like other, more common over-the-counter medications. With the production changes we've implemented over the past six weeks, we are confident that we can now fulfill increase in demand for the product."

For more information, visit www.flemingpharma.com or www.thyroshield.com.


'/>"/>
SOURCE Fleming Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Media Statement on Nuclear Crisis in Japan: Fleming Pharmaceuticals Stepping Up Production of Nuclear Antidote
2. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
3. Hanmi Pharmaceuticals to Acquire the Rights for a Promising Phase II Anti-cancer Src Kinase/Pretubulin Dual Inhibitor from Kinex Pharmaceuticals, in Selected Asian Territories
4. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
5. Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013
6. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
7. Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
10. Bexion Pharmaceuticals Receives Outstanding Biotech Innovation Award
11. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
Breaking Medicine Technology:
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes ... of the facility as part of a disaster drill on October 3rd. , Apple ... Shelton City Emergency Manager, as well as the Connecticut Long Term Care Mutual ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... 2017 , ... Talented host, actor Rob Lowe, is introducing ... new episode of "Success Files," which is an award-winning educational program broadcasted on ... subject in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):